(Q42940913)

11 November 2017

title

Flows and flaws in primary central nervous system lymphoma (English)

1 reference

11 November 2017

Emanuele Zucca

3

0 references

Franco Cavalli

series ordinal

4

object named as

Franco Cavalli

1 reference

11 November 2017

Andrés J M Ferreri

1

1 reference

11 November 2017

Gerald Illerhaus

series ordinal

2

1 reference

11 November 2017

International Extranodal Lymphoma Study Group

series ordinal

5

1 reference

11 November 2017

language of work or name

English

0 references

publication date

1 August 2010

1 reference

Nature Reviews Clinical Oncology

11 November 2017

published in

1 reference

11 November 2017

volume

7

1 reference

11 November 2017

issue

8

1 reference

11 November 2017

page(s)

doi:10.1038/nrclinonc.2010.9-c1; author reply doi:

1 reference

https://scigraph.springernature.com/pub.10.1038/nrclinonc.2010.9-c1

11 November 2017

exact match

0 references

cites work

Hematology: Trials and tribulations in primary CNS lymphoma

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.9-C1

High-dose chemotherapy supported by autologous stem cell transplantation in patients with primary central nervous system lymphoma: facts and opinions

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.9-C1

High-dose chemotherapy and autologous stem-cell transplantation without consolidating radiotherapy as first-line treatment for primary lymphoma of the central nervous system

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.9-C1

Primary central nervous system lymphoma treated with high-dose methotrexate, high-dose busulfan/thiotepa, autologous stem-cell transplantation and response-adapted whole-brain radiotherapy: results of the multicenter Ostdeutsche Studiengruppe Hamato

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.9-C1

Treatment of primary CNS lymphoma with methotrexate and deferred radiotherapy: a report of NABTT 96-07.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.9-C1

NOA-03 trial of high-dose methotrexate in primary central nervous system lymphoma: final report.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.9-C1

High-dose cytarabine plus high-dose methotrexate versus high-dose methotrexate alone in patients with primary CNS lymphoma: a randomised phase 2 trial.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.9-C1

State-of-the-art therapeutics: diffuse large B-cell lymphoma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.9-C1

Cognitive functions in primary central nervous system lymphoma: literature review and assessment guidelines

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.9-C1

Prognostic scoring system for primary CNS lymphomas: the International Extranodal Lymphoma Study Group experience

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.9-C1

10.1038/NRCLINONC.2010.9-C1

31 March 2020

Identifiers

DOI

1 reference

Dimensions Publication ID

11 November 2017

1028338161

0 references

1 reference